Longitudinal case series study in individuals with chromomycosis treated with azoles in the public health system of Brasília, Brazil
Estudo longitudinal, tipo série de casos, em indivíduos portadores de cromomicose, tratados com azólicos, realizado no sistema de saúde pública em Brasília, Brasil
Palavras-chave:
Chromomycosis, Fonsecaea pedrosoi, Treatment, Itraconazole, VoriconazoleResumo
Chromomycosis is a chronic skin disease caused by fungi. This study aims to evaluate the use of itraconazole and voriconazole (azoles) in the treatment of chromomycosis. It is a descriptive longitudinal case series study conducted in Brasília, Brazil, between March 2007 and February 2020. Data were collected from 21 individuals diagnosed with chromomycosis treated with azoles, 18 men and 3 women. Data analysis was performed using IBM SPSS (Statistical Package for the Social Sciences) 21, 2015. The predominant etiological agent in the study was Fonsecaea pedrosoi(95.24%). The main clinical presentations of the disease in participants were erythematous plaque (52.38%) and verrucous form (38.10%). Of the individuals in the study, 19.05% showed no improvement, 61.9% achieved improvement, and 19.05% achieved clinical and laboratory cure. Therefore, azoles demonstrated high efficacy and safety in the treatment of chromomycosis. Itraconazole proved to be a good choice, while voriconazole showed superior results. The findings indicate promising prospects for the treatment of chromomycosis.
Downloads
Referências
Ameen, M. Chromoblastomycosis: clinical presentation and management. Clinical and Experimental Dermatology, v. 34, n. 8, p. 849–854, dez. 2009.
Andrade, T. S. de et al. Chromoblastomycosis in the Amazon region, Brazil, caused by Fonsecaea pedrosoi, Fonsecaea nubica, and Rhinocladiella similis: Clinicopathology, susceptibility, and molecular identification. Medical Mycology, 24 apr. 2019.
Bonifaz, A.; Carrasco-Gerard, E.; Saul, A. Chromoblastomycosis: clinical and mycologic experience of 51 cases. Mycoses, v. 44, n. 1-2, p. 1–7, 2001.
Coelho, R. A. et al. Molecular identification and antifungal susceptibility profiles of clinical strains of Fonsecaea spp. isolated from patients with chromoblastomycosis in Rio de Janeiro, Brazil. PLOS Neglected Tropical Diseases, v. 12, n. 7, p. e0006675, 26 jul. 2018.
Correia, R. T. M. et al. Cromoblastomicose: relato de 27 casos e revisão da literatura. Anais Brasileiros de Dermatologia, v. 85, n. 4, p. 448–454, ago. 2010.
Criado, P. R. et al. Extensive long-standing chromomycosis due to Fonsecaea pedrosoi: Three cases with relevant improvement under voriconazole therapy. Journal of Dermatological Treatment, v. 22, n. 3, p. 167–174, 28 jul. 2010.
De Brito, A. C.; Bittencourt, M. de J. S. Chromoblastomycosis: an etiological, epidemiological, clinical, diagnostic, and treatment update. Anais Brasileiros de Dermatologia, v. 93, n. 4, p. 495–506, 2018.
Greer, N. D. Voriconazole: The Newest Triazole Antifungal Agent. Baylor University Medical Center Proceedings, v. 16, n. 2, p. 241–248, abr. 2003.
Koehler, A. et al. Melanin and chromoblastomycosis agents: Characterization, functions, and relation with antifungals. Journal of Basic Microbiology, v. 61, n. 3, p. 203–211, 12 feb. 2021.
Piérard, G.; Arrese, J.; Piérard-Franchimont, C. Itraconazole. Expert Opinion on Pharmacotherapy, v. 1, n. 2, p. 287–304, jan. 2000.
Queiróz, A. J. R.; Pereira Domingos, F.; Antônio, J. R. Chromoblastomycosis: clinical experience and review of literature. International Journal of Dermatology, v. 57, n. 11, p. 1351–1355, 16 ago. 2018.
Queiroz-Telles, F. et al. Chromoblastomycosis: an overview of clinical manifestations, diagnosis and treatment. Medical Mycology, v. 47, n. 1, p. 3–15, jan. 2009.
Queiroz-Telles, F. et al. Chromoblastomycosis. Clinical Microbiology Reviews, v. 30, n. 1, p. 233–276, 1 jan. 2017.
Queiroz-Telles, F. et al. Itraconazole in the treatment of chromoblastomycosis due to Fonsecaea pedrosoi. International Journal of Dermatology, v. 31, n. 11, p. 805–812, 1 nov. 1992.
Queiroz-Telles, F. et al. Mycoses of implantation in Latin America: an overview of epidemiology, clinical manifestations, diagnosis and treatment. Medical Mycology, v. 49, n. 3, p. 225–236, abr. 2011.
Queiroz-Telles, F. et al. Neglected endemic mycoses. The Lancet Infectious Diseases, v. 17, n. 11, p. e367–e377, nov. 2017.
Queiroz-Telles, F. et al. Subcutaneous mycoses. Infectious Disease Clinics of North America, v. 17, n. 1, p. 59–85, mar. 2003.
Ribeiro, E. L. et al. Cromoblastomicose: Doença presente na realidade populacional brasileira. Revista Brasileira de Análises Clínicas, p. 189–192, 2006.
Santos, D. W. C. L. et al. The global burden of chromoblastomycosis. PLOS Neglected Tropical Diseases, v. 15, n. 8, p. e0009611, 12 ago. 2021.
Veronesi, R.; Focaccia, R.; et al. Tratado de infectologia. São Paulo (SP): Atheneu, 2015.
